CORONARY HEART DISEASE, HAGEMAN FACTOR, HORMONAL CONTROL
冠心病、哈格曼因子、荷尔蒙控制
基本信息
- 批准号:3073801
- 负责人:
- 金额:$ 5.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-02-01 至 1990-01-31
- 项目状态:已结题
- 来源:
- 关键词:bromocriptine coagulation factor VII coagulation factor XII coronary disorder corticosterone dexamethasone endocrine pharmacology estradiol estrogens female antifertility drug hormone regulation /control mechanism human subject immunoelectrophoresis liver function prednisone pregnancy toxemia /hypertension prolactin radioimmunoassay renin sickle cell crisis thrombosis
项目摘要
The long-term goal of this study is to gain insight into the mechanisms
involved in the development of thrombosis in men with coronary heart
disease and other individuals who are at statistical risk. A possible
cause of thrombosis is a state of "hypercoagulability", for example,
abnormally high titers of clotting factors in plasma. In women using oral
contraceptives containing estrogenic compounds, as well as pregnant women,
the plasma titer of Hageman factor (HF, factor XII) is doubly elevated.
The cold-induced increase in factor VII and plasma renin activities
observed in women using oral contraceptives reflect their high HF titers.
Recently, the Framingham Heart Study reported that men with coronary heart
disease have hyperestrogenemia. Since estrogens increase prolactin
secretion, both estrogen and prolactin may play a role in raising HF titer,
possibly by affecting protein synthesis. This project will study the
mechanisms involved in HF activation, synthesis and catabolism, as well as
the hormonal control of its titer in plasma. The specific objectives are:
1) to determine whether men with coronary heart disease have high HF
titers, and whether their plasmas manifest enhanced cold-activation of
factor VII and prorenin, HF coagulant and antigen titers, plasma renin and
factor VII activities will be measured in fresh and cold-stored plasmas and
will be related to their estradiol and prolactin titers; 2) to determine
whether the high HF titer observed in estradiol, prolactin and
dexamethasone-treated rats is due to de novo synthesis or decreased
degradation of HF, liver perfusion techniques and in vivo catabolism
studies will be performed; 3) to determine whether the inhibition of
prolactin secretion will reduce HF titer, HF titer will be measured in
bromocriptine-treated rats; 4) to determine whether the thromboembolic and
hypertensive complications of pregnancy are related to high HF titer, a
longitudinal study of women throughout their pregnancy will be performed
using methods in the study of men with coronary heart disease; 5) to
determine whether corticosteroid therapy raises HF titer in humans, HF
coagulant and antigen titers will be measured in patients receiving
decadron or prednisone; 6) to determine whether an activated HF-C1 esterase
inhibitor complex is formed in women using oral contraceptives and in
sickle cell patients during vaso-occlusive crises, crossed
immunoelectrophoretic techniques will be used. Statistical methods of
analyses will include the Student's t test, Pearson's coefficient of
correlation and multiple correlation.
这项研究的长期目标是深入了解其机制
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERLINDA M GORDON其他文献
ERLINDA M GORDON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERLINDA M GORDON', 18)}}的其他基金
CORONARY HEART DISEASE, HAGEMAN FACTOR, HORMONAL CONTROL
冠心病、哈格曼因子、荷尔蒙控制
- 批准号:
3073805 - 财政年份:1989
- 资助金额:
$ 5.31万 - 项目类别:
CORONARY HEART DISEASE, HAGEMAN FACTOR, HORMONAL CONTROL
冠心病、哈格曼因子、荷尔蒙控制
- 批准号:
3073804 - 财政年份:1985
- 资助金额:
$ 5.31万 - 项目类别:
CORONARY HEART DISEASE, HAGEMAN FACTOR, HORMONAL CONTROL
冠心病、哈格曼因子、荷尔蒙控制
- 批准号:
3073802 - 财政年份:1985
- 资助金额:
$ 5.31万 - 项目类别:
CORONARY HEART DISEASE, HAGEMAN FACTOR, HORMONAL CONTROL
冠心病、哈格曼因子、荷尔蒙控制
- 批准号:
3073803 - 财政年份:1985
- 资助金额:
$ 5.31万 - 项目类别:
CORONARY HEART DISEASE, HAGEMAN FACTOR, HORMONAL CONTROL
冠心病、哈格曼因子、荷尔蒙控制
- 批准号:
3073800 - 财政年份:1985
- 资助金额:
$ 5.31万 - 项目类别:
相似海外基金
Effect of ectopically synthesized coagulation factor VII on venous thromboembolism and malignancy
异位合成凝血因子VII对静脉血栓栓塞和恶性肿瘤的影响
- 批准号:
18K08346 - 财政年份:2018
- 资助金额:
$ 5.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Coagulation factor VII producing tumors and their release of microparticles with coagulation initiating capacity
产生凝血因子VII的肿瘤及其释放具有凝血启动能力的微粒
- 批准号:
21590455 - 财政年份:2009
- 资助金额:
$ 5.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
REGULATION OF EXPRESSION OF COAGULATION FACTOR VII
凝血因子VII表达的调节
- 批准号:
6388396 - 财政年份:1997
- 资助金额:
$ 5.31万 - 项目类别:
REGULATION OF EXPRESSION OF COAGULATION FACTOR VII
凝血因子VII表达的调节
- 批准号:
2027178 - 财政年份:1997
- 资助金额:
$ 5.31万 - 项目类别:
REGULATION OF EXPRESSION OF COAGULATION FACTOR VII
凝血因子VII表达的调节
- 批准号:
6182399 - 财政年份:1997
- 资助金额:
$ 5.31万 - 项目类别:
REGULATION OF EXPRESSION OF COAGULATION FACTOR VII
凝血因子VII表达的调节
- 批准号:
6030393 - 财政年份:1997
- 资助金额:
$ 5.31万 - 项目类别:
REGULATION OF EXPRESSION OF COAGULATION FACTOR VII
凝血因子VII表达的调节
- 批准号:
2734980 - 财政年份:1997
- 资助金额:
$ 5.31万 - 项目类别: